Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Shanghai Menon Animal Nutrition Technology
301156
5
Nanjing Railway New Technology
301016
CN Stock MarketDetailed Quotes
688488 Jiangsu Aidea Pharmaceutical
- 11.22
- -0.23-2.01%
Market Closed Apr 3 15:00 CST
4.72BMarket Cap-45.24P/E (TTM)
11.77High10.82Low137.90KlotVolume11.20Open11.45Pre Close154.98MTurnover3.28%Turnover RatioLossP/E (Static)420.78MShares17.3352wk High4.42P/B4.72BFloat Cap6.5852wk Low13.74Limit Up420.78MShs Float45.21Historical High9.16Limit Down8.30%Amplitude6.58Historical Low--Dividend TTM11.24Avg Price71.05KlotAsk--Div YieldTTM100Lot Size62.02KlotBid
Jiangsu Aidea Pharmaceutical News
The "wind" has reached the pharmaceutical stocks, and the Sector is experiencing a surge in limit-up prices! What are the Bullish catalysts?
Catalysts from news, warming performance, and the advantages of valuation may become the main factors boosting the rise of pharmaceutical stocks.
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Jiangsu Aidea Pharmaceutical Gets Clinical Trial Approval for AD108 Injection
Jiangsu Aidea Pharmaceutical (688488.SH): AD108 injection has received the drug clinical trial approval notice.
On March 13, 2023, Gelonghui reported that Jiangsu Aidea Pharmaceutical (688488.SH) announced that the company and its holding subsidiary, Nanjing Nanda Pharmaceutical Co., Ltd., received the "Notice of Drug Clinical Trial Approval" (referred to as the "Notice") issued by the National Medical Products Administration on March 12, 2025, approving the company to conduct Phase I clinical trials of the 2.2 class modified new drug AD108 injection. AD108 injection is a modified new drug (Chemical Drug class 2.2), with the active ingredient being human prorenin enzyme, specifically tissue type kallikrein-1 (KLK-1), which is a serine protease secreted by the kidneys.
Jiangsu Aidea Pharmaceutical Co., Ltd. (SHSE:688488) Looks Just Right With A 28% Price Jump
Eddy Pharmaceuticals 2024 Annual Results Express Announcement
Jiangsu Aidea Pharmaceutical (688488.SH): Net loss of 0.13 billion yuan for the year 2024.
Gelonghui February 27丨Jiangsu Aidea Pharmaceutical (688488.SH) announced the performance report for 2024. During the reporting period, the company's total operating revenue was 419.265 million yuan, an increase of 1.92% compared to the same period last year; the operating profit was -151.8265 million yuan, which is a decrease of 64.94% compared to the same period last year; the total profit was -153.0564 million yuan, which represents a decrease of 66.21% compared to the same period last year; the net income attributable to the owners of the parent company was -129.9185 million yuan, a decrease of 70.79% compared to the same period last year; the net income attributable to the owners of the parent company after deductions.
Eddy Pharmaceuticals 2024 Annual Results Forecast
Jiangsu Aidea Pharmaceutical (688488.SH): Elected Fu Heling as Director.
Gelonghui, January 3rd丨Jiangsu Aidea Pharmaceutical (688488.SH) announced that on January 3, 2025, the company will hold the first meeting of the third Board of Directors, where all directors unanimously agreed to elect Mr. Fu Helian as the chairman of the third Board of Directors.
Jiangsu Aidea Pharmaceutical (688488.SH): New core technical personnel identified as Qin Hong, Li Qide, and Sun Tie.
Jiangsu Aidea Pharmaceutical (688488.SH) issued a notice that the company's senior management and core technical personnel Hong ...
Insiders With Their Considerable Ownership Were the Key Benefactors as Jiangsu Aidea Pharmaceutical Co., Ltd. (SHSE:688488) Touches CN¥4.1b Market Cap
Eddy Pharmaceuticals: Eddy Pharmaceuticals Third Quarter 2024 Report
Eddy Pharmaceuticals 2024 Third Quarter Report
Director and Vice President Wang Jun of Jiangsu Aidea Pharmaceutical (688488.SH) completed the shareholding of 0.6921 million shares.
Jiangsu Aidea Pharmaceutical (688488.SH) announced that the director and vice president Wang Jun has cumulatively reduced his shareholding through centralized bidding...
China Accepts Jiangsu Aidea Pharma's New Indication for HIV Medication
Investor Optimism Abounds Jiangsu Aidea Pharmaceutical Co., Ltd. (SHSE:688488) But Growth Is Lacking
Jiangsu Aidea Pharmaceutical Withdraws Marketing Authorization Application for HIV Tablets
Jiangsu Aidea Pharmaceutical (688488.SH): Withdrawal of the new indication application for Aino Weilin tablets.
Gelonghui September 26th | jiangsu aidea pharmaceutical (688488.SH) announced that the company has scientifically formulated differentiated market strategy based on evidence-based medicine data, product characteristics, patent duration, etc. for antiretroviral drugs. According to the company's market strategy, the company has proactively applied to withdraw the marketing authorization application for the new indication of enofovir tablets, and has recently obtained approval from the National Medical Products Administration. As of the date of this announcement, the single-compound formulation of enofoside tablets containing enofoside as an ingredient has made smooth progress in the application for new indications, and its marketing authorization application has completed the technical review work, and is currently in the process of document preparation and review and approval. The company will continue
Star Evening News | Xi'an Bright Laser Technologies plans to invest 1 billion yuan to build a material production line. Jiangsu Aidea Pharmaceutical has completed the acquisition of 31.161% equity of Nanda Pharmaceuticals.
1. Guangdong Jiayuan Technology signed the "Investment Intention Termination Agreement" with the Meixian District People's Government of Meizhou City; 2. Xi'an Bright Laser Technologies, opt machine vision tech co., ltd., NAIKE Equipment disclosed the repurchase plan; 3. Shanghai Allist Pharmaceuticals Co., Ltd.: AST2303 slice obtained the drug clinical trial approval notice.
Aidea Pharma Pledges Subsidiary's 51% Stake for 90 Million Yuan Loan; Shares Drop 5%